| Nov 13 |
Astria TherapeuticS GAAP EPS of -$0.42 in-line
|
| Nov 13 |
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
|
| Nov 13 |
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
|
| Oct 30 |
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
|
| Oct 21 |
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
|
| Oct 18 |
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth
|
| Oct 16 |
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
|
| Sep 30 |
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
|
| Sep 27 |
Astria Therapeutics to Present at Upcoming Global Angioedema Forum
|
| Sep 19 |
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
|
